Search This Blog

Monday, December 2, 2019

Astellas Pharma to buy Audentes Therapeutics for $60/share

Audentes Therapeutics (NASDAQ:BOLD) agrees to be acquired by Astellas Pharma (OTCPK:ALPMF) for US$60/share in cash, representing a total equity value of ~US$3B; shares are halted.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)